Immunopathogenesis of HIV infection

Annual Review of Microbiology

Volumn 50, Issue , 1996, Pages 825-854

  Pantaleo, G ^a   Fauci, A S ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

immunologic events; mechanisms of virus escape; primary infection; virologic events

Indexed keywords

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CELLULAR IMMUNITY; DISEASE COURSE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; IMMUNOPATHOGENESIS; NONHUMAN; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE; VIRUS PATHOGENESIS;

CLONAL DELETION; DISEASE PROGRESSION; HIV; HIV INFECTIONS; HUMANS; IMMUNOCOMPROMISED HOST; LYMPHOID TISSUE; MODELS, BIOLOGICAL; T-LYMPHOCYTES, CYTOTOXIC; TIME FACTORS; VIREMIA; VIRUS LATENCY;

HUMAN IMMUNODEFICIENCY VIRUS;

EID: 0029820873     PISSN: 00664227     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.micro.50.1.825     Document Type: Review

References (103)

1. Abrams DI, Lewis BJ, Beckstead JH, Casavant CA, Drew WL. 1984. Persistent diffuse lymphadenopathy in homosexual men: endpoint or prodrome? Ann. Intern. Med. 100:801-8
2. Armstrong JA, Dawkins RL, Horne R. 1985. Retroviral infection of accessory cells and the immunological paradox in AIDS. Immunol. Today 6:121-22
3. Asjo B, Sharma UK, Morfeldt-Manson L, Magnusson A. 1990. Naturally occurring HIV-1 isolates with differences in replicative capacity are distinguished by in situ hybridization of infected cells. AIDS Res. Hum. Retroviruses 6:1177-82
4. Autran B, Leqac E, Blanc C, Debre PA. 1995. Tho-Th2-like function of CD4+ CD7-T helper cells from normal donors and HIV infected patients. J. Immunol. 154:1408-17
5. Baier M, Werner A, Bannert N, Metzner K, Kurth R. 1995. HIV suppression by interleukin-16. Nature 378:563
6. Berman PW, Gregory TJ, Riddle L, Nakamura GR, Champe MA, et al. 1990. Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160. Nature 345:622-25
7. Borrow P, Lewicki H, Hahn BH, Shaw GM, Oldstone MB. 1994. CTL activity associated with control of viremia in primary HIV-1 infection. J. Virol. 68:6103-10
8. Bou-Habib DC, Roderiquez G, Oravecz T, Berman PW, Lusso P, et al. 1994. Cryptic nature of envelope V3 region epitopes protects primary monocytotropic human immunodeficiency virus type 1 from antibody neutralization. J. Virol. 68:6006-13
9. Broder CC, Earl PL, Long D, Abedon ST, Moss B, et al. 1994. Antigenic implications of human immunodeficiency virus type 1 envelope quaternary structure: oligomer-specific and -sensitive monoclonal antibodies. Proc. Natl. Acad. Sci. USA 91:11699-11703
10. Buchbinder SP, Katz MH, Hessol NA, O'Malley PM, Holmberg SD. 1994. Long-term HIV-infection without immunologic progression. AIDS 8:1123-28
11. Bukrinsky MI, Stanwick TL, Dempsey MP, Stevenson M. 1991. Quiescent T lymphocytes as an inducible virus reservoir in HIV-1 infection. Science 18:423-27
12. Cao Y, Quin L, Zhang L, Safrit J, Ho DD. 1995. Virologic and immunologic characterization of long-term survivors of human immunodeficiency virus type 1 infection. N. Engl. J. Med. 26:201-8
13. Chakrabarti L, Isola P, Cumont M-C, Claessens-Maire M-A, Hurtrel M, et al. 1994. Early stages of simian immunodeficiency virus infection in lymph nodes. Am. J. Pathol. 144:1226-34
14. Cheng-Mayer C, Homsy J, Evans LA, Levy JA. 1988. Identification of human immunodeficiency virus subtypes with distinct patterns of sensitivity to serum neutralization. Proc. Natl. Acad Sci. USA 85:2815-19
15. Clark SJ, Saag MS, Decker WD, Campbell-Hill S, Roberson JL, et al. 1991. High titers of cytopathic virus in plasma of patients with symptomatic primary HIV-1 infection. N. Engl. J. Med. 324:954-60
16. Clerici M, Shearer GM. 1993. ATH1 TH2 switch is a critical step in the etiology of HIV infection. Immunol. Today 14:107-11
17. Clerici M, Stocks NI, Zajac RA, Boswell RN, Bernstein DC, et al. 1989. Interleukin-2 production used to detect antigenic peptide recognition by T-helper lymphocytes from asymptomatic HIV-seropositive individuals. Nature 339:383-85
18. Cocchi F, DeVico AL, Garzino-Demo A, Arya SK, Gallo RC, et al. 1995. Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive factors produced by CD8+ T cells. Science 270:1811-15
19. Coffin JM. 1995. HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Science 267:483-89
20. Cohen OJ, Pantaleo G, Holodniy, Schnittman S, Niu M, et al. 1995. Decreased human immunodeficiency virus type 1 plasma viremia during antiretroviral therapy reflects downregulation of viral replication in lymphoid tissue. Proc. Natl. Acad. Sci. USA 92:6017-21
21. Daar ES, Moudgil T, Meyer RD, Ho DD. 1991. Transient high levels of viremia in patients with primary human immunodeficiency virus type 1 infection. N. Engl. J. Med. 324:961-64
22. Denis M, Ghadirian E. 1994. Mycobacterium avium infection in HIV-1-infected subjects increases monokine secretion and is associated with enhanced viral load and diminished immune response to viral antigens. Clin. Exp. Immunol. 97:76-82
23. Easterbrook PJ. 1994. Non-progression in HIV infection. AIDS 8:1179-82
24. Embretson J, Zupancic M, Ribas JL, Burke A, Tenner-Racz K, et al. 1993. Massive covert infection of helper T lymphocytes and macrophages by HIV during the incubation period of AIDS. Nature 362:359-62
25. Emilie D, Peuchmaur M, Maillot M, Crevon M, Brousse N, et al. 1990. Production of interleukins in human immunodeficiency virus-1-replicating lymph nodes. J. Clin. Invest. 86:148-59
26. Emini EA, Nara PL, Schlief Wa. 1990. Antibody-mediated in vitro neutralization of human immunodeficiency virus type 1 abolishes infectivity for chimpanzees. J. Virol. 64:3674-78
27. Fauci AS. 1993. Multifactorial nature of human immunodeficiency virus diseases: implications for therapy. Science 262:1011-18
28. Fauci AS, Lane HC. 1991. The acquired immunodeficiency syndrome (AIDS). In Harrison's Principles of Internal Medicine, Vol 2, ed. JD Wilson, E Braunwald, KJ Isselbacher, et al, pp. 1402-10, 12th ed. New York: McGraw-Hill
29. Fauci AS, Masur H, Gelmann EP, Markham PD, Hahn BH, et al. 1985. NIH Conference. The acquired immunodeficiency syndrome: an update. Ann. Intern. Med. 102:800-13
30. Fox CH, Tenner-Racz K, Racz P, Firpo A, Pizzo PA, et al. 1991. Lymphoid germinal centers are reservoirs of human immunodeficiency virus type 1 RNA. J. Infect. Dis. 164:1051-57
31. Girard M, Kieny M-P, Pinter A. 1991. Immunization of chimpanzees confers protection against challenge with human immunodeficiency virus. Proc. Natl. Acad. Sci. USA 88:542-46
32. Graziosi C, Gantt KR, Vaccareza M, Demarest JF, Daucher MB, et al. Kinetics of cytokine expression during primary human immunodeficiency virus type 1 (HIV-1) infection. Proc. Natl. Acad. Sci. USA. In press
33. Graziosi C, Pantaleo G, Butini L, Demarest JF, Saag MS, et al. 1993. Kinetics of HIV DNA and RNA synthesis during primary HIV-1 infection. Proc. Natl. Acad. Sci. USA 90:6505-9
34. Graziosi C, Pantaleo G, Gantt KR, Demarest JF, Cohen OJ, Fauci AS. 1994. Lack of evidence for dichotomy of TH1 and Th2 predominance in HIV-infected individuals. Science 265:248-52
35. Guidotti LG, Ishikawa T, Hobbs MV, Matzke B, Schrieber, Chisari FV. 1996. Intracellular inactivation of the hepatitis B virus by cytotoxic T lymphocytes. Immunity 4:25-36
36. Haynes BF. 1992. Immune responses to HIV infection. In AIDS, Etiology, Diagnosis, Treatment and Prevention, ed. VT DeVita, S Hellman, SA Rosenberg, pp. 77-86, 3rd ed. Philadelphia: Lippincott-
37. Haynes BF, Pantaleo G, Fauci AS. 1996. Toward an understanding of the correlates of protective immunity to HIV infection. Science 271:324-28
38. Health SL, Tew JG, Szakal AK, Burton GF. 1995. Follicular dendritic cells and human immunodeficiency virus. Nature 377:740-44
39. Heng MCY, Heng SY, Allen SG. 1994. Co-infection and synergy of human immunodeficiency virus-1 and herpes simplex virus-1. Lancet 343:255-58
40. Ho DD. 1992. HIV-1 viraemia and influenza. Lancet 339:1549
41. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, et al. 1995. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 373:123-26
42. Homsy J, Meyer M, Levy J. 1990. Serum enhancement of human immunodeficiency virus (HIV) infection correlates with disease in HIV-infected individuals. J. Virol. 64:1437-40
43. Israel-Biet D, Cadranel J, Even P. 1993. Human immunodeficiency virus production by alveolar lymphocytes is increased during Pneumocystis carinii pneumonia. Am. Rev. Respir. Dis. 148:1308-12
44. Kirchhoff F, Greenough TC, Brettler DB, Sullivan L, Desrosiers RC. 1995. Brief report: absence of intact nef sequences in long-term survivor with non progressive HIV-1 infection. N. Engl. J. Med. 332:228-32
45. Koot M, Keet IPM, Vos AHV, DeGoede REY, Roos MTHL, et al. 1993. Prognostic value of human immunodeficiency virus type 1 biological phenotype for rate of CD4+ cell depletion and progression to AIDS. Ann. Intern. Med. 118:681-88
46. Koup RA, Safrit JT, Cao Y, Andrews CA, McLeod G, et al. 1994. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J. Virol. 68:4650-55
47. Laal S, Burda S, Gorny MK, Karwowska S, Buchbinder A, et al. 1994. Synergistic neutralization of human immunodeficiency virus type 1 by combinations of human monoclonal antibodies. J. Virol. 68:4001-8
48. Levy JA. 1993. HIV pathogenesis and long-term survival. AIDS 7:1401-10
49. Lifson AR, Buchbinder SP, Sheppard HW. 1991. Long-term human immunodeficiency virus infection in asymptomatic homosexual and bisexual men with normal CD4+ lymphocyte counts: immunologic and virologic characteristics. J. Infect. Dis. 163:959-65
50. Mackewicz CE, Yang LC, Lifson JD, Levy JA. 1994. Non-cytolytic CD8 T-cell anti-HIV responses in primary HIV-1 infection. Lancet 344:1671-1673
51. Mackewicz CF, Ortega HW, Levy JA. 1991. CD8+ cell anti-HIV activity correlates with the clinical state of the infected individuals. J. Clin. Invest. 87:1462-66
52. Maggi E, Mazzetti M, Ravina A, Annunziato F, DeCarli M, et al. 1994. Ability of HIV to promote a TH11 to TH0 shift and to replicate preferentially in TH2 and THO cells. Science 265:244-48
53. Maryanski JL, Jongeneel CV, Bucher P, Casanova J-L, Walker PR. 1996. Single-cell PCR analysis of TCR repertoires selected by antigen in vivo: A high magnitude CDS response is comprised of very few clones. Immunity 4:47-55
54. Matthews TJ, Langlois AJ, Robey WG, Chang NT, Gallo RC, et al. 1986. Restricted neutralization of divergent human T-lymphotropic virus type III isolates by antibodies to the major envelope glycoprotein. Proc. Natl. Acad. Sci. USA 83:9709-13
55. McKeating JJ, Cordell J, Dean CJ, Balfe P. 1992. Synergistic interaction between ligands binding to the CD4 binding site and V3 domain of human immunodeficiency virus type 1 gp120. Virology 191:732-42
56. Meier UC, Klenerman P, Griffin P, James W, Koppe B, et al. 1995. Cytotoxic T lymphocyte lysis inhibited by viable HIV mutants. Science 270:1360-62
57. Meyaard L, Otto SA, Keet IP, van Lier RAW, Miedema F. 1994. Changes in cytokine secretion patterns of CD4+ T-cell clones in human immunodeficiency virus infection. Blood 84:4262-68
58. Montefiori DC, Graham BS, Zhou J, Zhou J, Bucco RA, et al. 1993. V3-spacific neutralizing antibodies in sera from HIV-1 gp160-immunized volunteers block virus fusion and act synergistically with human monoclonal antibody to the conformation-dependent CD4 binding site of gp120. J. Clin. Invest. 92:840-47
59. Moore JP, Cao Y, Ho DD, Koup RA. 1994. Development of the anti-gp120 antibody responses during seroconversion to human immunodeficiency virus type 1. J. Virol 68:5142-55
60. Pantaleo G, Demarest JF, Soudeyns H, Graziosi C, Denis F, et al. 1994. Major expansion of CD8+ T cells with a predominant V usage during the primary immune response to HIV. Nature 370:463-67
61. Pantaleo G, Demarest JF, Vaccarezza M, Graziosi C, Bansal GP, et al. 1995. Effect of anti-V3 antibodies on cell-free and cell-to-cell human immunodeficiency virus transmission. Eur. J. Immunol. 25:226-31
62. Pantaleo G, Fauci AS. 1994. Tracking HIV during disease progression. Curr. Opin. Immunol. 6:600-4
63. Pantaleo G, Craziosi C, Fauci AS. 1993. The role of lymphoid organs in the pathogenesis of HIV infection. Sem. Immunol. 5:157-63
64. Pantaleo G, Fauci AS. 1995. New concepts in the immunopathogenesis of HIV infection. Annu. Rev. Immunol. 13:487-512
65. Pantaleo G, Graziosi C, Butini L, Pizzo PA, Schnittman SM, et al. 1991. Lymphoid organs function as major reservoirs for human immunodeficiency virus. Proc. Natl. Acad. Sci. USA 88:9838-42
66. Pantaleo G, Graziosi C, Demarest JF, Butini L, Montroni M, et al. 1993. HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease. Nature 362:355-59
67. Pantaleo G, Graziosi C, Demarest JF, Cohen OJ, Vaccarezza M, et al. 1994. Role of lymphoid organs in the pathogenesis of human immunodeficiency virus (HIV) infection. Immunol. Rev. 140:105-30
68. Pantaleo G, Graziosi C, Fauci AS. 1993. The immunopathogenesis of human immunodeficiency virus infection. N. Engl. J. Med. 328:327-35
69. Pantaleo G, Graziosi C, Fauci AS. 1993. The role of lymphoid organs in the immunopathogenesis of HIV infection. AIDS 7:S19-S23
70. Pantaleo G, Menzo S, Vaccarezza M, Graziosi C, Cohen OJ, et al. 1995. Studies in subjects with long-term nonprogressive human immunodeficiency virus infection. N. Engl. J. Med. 332:209-16
71. Phair JP. 1994. Keynote address: variations in the natural history of HIV infection. AIDS Res. Hum. Retroviruses 10:883-85
72. Phillips RE, Rowland-Jones S, Nizon DF, Gotch FM, Edwards JP, et al. 1991. Human immunodeficiency virus genetic variation that can escape cytotoxic T cell recognition. Nature 354:453-59
73. Piatak M, Saag MS, Yang LC, Clark SJ, Kappes JC, et al. 1993. High levels of HIV-1 in plasma during all stages of infection determined by competitive PCR. Science 259:1749-54
74. Poli G, Fauci AS. 1992. The effect of cytokines and pharmacologic agents on chronic HIV infection. AIDS Res. Hum. Retroviruses 8:191-97
75. Poli G, Pantaleo G, Fauci AS. 1993. Immunopathogenesis of human immunodeficiency virus infection. Clin. Infect. Dis. 17 (Suppl. 1):224-29
76. Price RW, Brew B, Sidtis J, Rosenblum M, Scheck AC, et al. 1988. The brain in AIDS: central nervous system HIV-1 infection and AIDS dementia complex. Science 239:586-92
77. Reimann KA, Tenner-Racz K, Racz P, Montefiori DC, Yasutomi Y, et al. 1994. Immunopathogenic events in acute infection of Rhesus monkeys with simian immunodeficiency virus of Macaques. J. Virol. 68:2362-70
78. Robert-Guroff M, Brown M, Gallo RC. 1985. HTLV-III-neutralizing antibodies in patients with AIDS and AIDS-related complex. Nature 316:72-74
79. Robinson WE, Montefiori DC, Mitchell W. 1989. Antibody-dependent enhancement of human immunodeficiency virus type 1 (HIV-1) infection in vitro by serum from HIV-1 infected and passively immunized chimpanzees. Proc. Natl. Acad. Sci. USA 86:4710-14
80. Robinson WE, Kawamura T, Gorny MK. 1990. Human monoclonal antibodies to the human immunodeficiency virus type 1 (HIV-1) transmembrane glycoprotein gp41 enhance HIV-1 infection in vitro. Proc. Natl. Acad. Sci. USA 87:3815-19
81. Salgame P, Abrams JS, Clayberger C, Goldstein H, Convit J, et al. 1991. Differing lymphokine profiles of functional subsets of human CD4 and CD8 T cell clones. Science 254:279-82
82. Sattentau QJ, Moore JP. 1995. Human immunodeficiency virus type 1 neutralization is determined by epitope exposure on the gp120 oligomer. J. Exp. Med. 182:185-96
83. Schellekens PT, Tersmette M, Roos MT, Keet RP, DeWolf F, et al. 1992. Biphasic rate of CD4+ cell count decline during progression to AIDS correlates with HIV-1 phenotype. AIDS 6:665-69
84. Schrager LJ, Young JM, Fowler MG, Mathieson BJ, Vermund SH. 1994. Long-term survivors of HIV-1 infection: definitions and research challenges. AIDS 8:S95-S108
85. Schuitemaker H, Koot M, Kootstra NA, Dercksen MW, de Goede REY, et al. 1992. Biological phenotype of human immunodeficiency virus type 1 clones at different stages of infection: Progression of disease is associated with a shift from monocytotropic to T-cell-tropic virus population. J. Virol. 66:1354-60
86. Seder RA, Grabstein KH, Berzofsky JA, McDyer JF. 1995. Cytokine interactions in human immunodeficiency virus-infected individuals: roles of interleukin (IL)-2, IL-12, and IL-15. J. Exp. Med. 182:1067-77
87. Sheppard HW. 1993. 9th Intl. Conf. AIDS. Berlin, June 6-11 9:46
88. Sheppard HW, Lang W, Ascher MS, Vittinghoff E, Winkelstein W. 1993. The characterization of non-progressors: long-term HIV-1 infection with stable CD4+ T-cell levels. AIDS 7:1159-66
89. Spiegel H, Herbst H, Niedobitek G, Foss HD, Stein H. 1992. Follicular dendritic cells are a major reservoir for human immunodeficiency virus type 1 in lymphoid tissues facilitating infection of CD4+ T-helper cells. Am. J. Pathol. 140:15-22
90. Sullivan N, Sun Y, Li J, Hofmann W, Sodroski J. 1995. Replication function and neutralization sensitivity of envelope glycoproteins from primary and T-cell line-passaged human immunodeficiency virus type 1 isolates. J. Virol. 69:4413-22
91. Tenner-Racz K, Racz P, Dietrich M, Karin P. 1985. Altered dendritic follicular cells and virus-like particles in AIDS and AIDS related lymphadenopathy. Lancet i:105-6
92. Tersmette M, de Goede RE, Al BJ, Winkel IN, Gruters RA, et al. 1988. Differential syncytium-inducing capacity of human immunodeficiency virus isolates: frequent detection of syncytium-inducing isolates in patients with acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. J. Virol. 62:2026-32
93. Tersmette M, Gruters RA, de Wolf F, de Goede RE, Lange JM, et al. 1989. Evidence for a role of virulent human immunodeficiency virus (HIV) variants in the pathogenesis of acquired immunodeficiency syndrome: studies on sequential HIV isolates. J. Virol. 63:2118-25
94. Tilley SA, Honnen WJ, Racho ME, Chou T-C, Pinter A. 1992. Synergistic neutralization of HIV-1 by human monoclonal antibodies against the V3 loop and the CD4-binding site of gp120. AIDS Res. Hum. Retroviruses 8:461-67
95. Tindall B, Cooper DA. 1991. Primary HIV infection: host responses and intervention strategies. AIDS 5:1-14
96. Torseth JW, Berman PW, Merigan TC. 1988. Recombinant HIV structural proteins detect specific cellular immunity in vitro in infected individuals. AIDS Res. Hum. Retroviruses 4:23-30
97. Urban JJ, Katona IM, Paul WE, Finkelman FD. 1991. Interleukin-4 is important in protective immunity to a gastrointestinal nematode infection in mice. Proc. Natl. Acad. Sci. USA 88:5513-17
98. Wei X, Ghosh SK, Taylor ME, Johnson VA, Emini EA, et al. 1995. Viral dynamics in human immunodeficiency virus type 1 infection. Nature 373:117-22
99. Weiss RA, Clapham RP, Cheingsong-Popov R, Dalgleish AG, Carne CA, et al. 1985. Neutralization of human T-lymphotropic virus type III by sera by AIDS and AIDS-risk patients. Nature 316:69-72
100. Weiss RA, Clapham R, Weber JN, Dalgleish AG. 1986. Variable and conserved neutralization antigens of human immunodeficiency virus. Nature 324:572-75
101. Zach JA, Arrigo SJ, Weitsman SR, Go AS, Haislip A, et al. 1990. HIV-1 entry into quiescent primary lymphocytes: Molecular analysis reveals a labile, latent viral structure. Cell 61:213-22
102. Zhang Y, Nakata K, Weiden M, Rom WN. 1995. Mycobacterium tuberculosis enhances human immunodeficiency virus-1 replication by transcriptional activation at the long terminal repeat. J. Clin. Invest. 95:2324-31
103. Zinkernagel RM. 1996. Immunology taught by viruses. Science 271:173-78